<div id=toc></div>

# Table of Contents

- [q-bio.BM](#q-bio.BM) [Total: 3]
- [cs.AI](#cs.AI) [Total: 2]
- [cs.LG](#cs.LG) [Total: 2]


<div id='q-bio.BM'></div>

# q-bio.BM [[Back]](#toc)

### [1] [IntFold: A Controllable Foundation Model for General and Specialized Biomolecular Structure Prediction](https://arxiv.org/abs/2507.02025)
*The IntFold Team,Leon Qiao,Wayne Bai,He Yan,Gary Liu,Nova Xi,Xiang Zhang*

Main category: q-bio.BM

TL;DR: IntFold是一种可控制的基础模型，在生物分子结构预测中表现出与AlphaFold3相当的准确性，同时采用定制注意力核。


<details>
  <summary>Details</summary>
Motivation: 开发一种既能预测一般结构，又能适应专业任务的生物分子结构预测模型。

Method: 使用定制注意力核和适配器技术，预测结构、变构状态、约束结构和结合亲和力，并引入新的置信度评估头。

Result: IntFold在准确性上媲美AlphaFold3，并在复杂目标（如抗体-抗原复合物）中提供了更细致的评估。

Conclusion: IntFold展示了其在生物分子结构预测中的多功能性和高效性，训练过程还为类似模型提供了宝贵经验。

Abstract: We introduce IntFold, a controllable foundation model for both general and
specialized biomolecular structure prediction. IntFold demonstrates predictive
accuracy comparable to the state-of-the-art AlphaFold3, while utilizing a
superior customized attention kernel. Beyond standard structure prediction,
IntFold can be adapted to predict allosteric states, constrained structures,
and binding affinity through the use of individual adapters. Furthermore, we
introduce a novel confidence head to estimate docking quality, offering a more
nuanced assessment for challenging targets such as antibody-antigen complexes.
Finally, we share insights gained during the training process of this
computationally intensive model.

</details>


### [2] [Downregulation of aquaporin 3 promotes hyperosmolarity-induced apoptosis of nucleus pulposus cells through PI3K/Akt/mTOR pathway suppression](https://arxiv.org/abs/2507.02231)
*Yuan Sang,Huiqing Zhao,Jiajun Wu,Ting Zhang,Wenbin Xu,Hui Yao,Kaihua Liu,Chang Liu,Junbin Zhang,Ping Li,Depeng Wu,Yichun Xu,Jianying Zhang,Gang Hou*

Main category: q-bio.BM

TL;DR: AQP3蛋白在高渗透压下减少，导致NPC细胞凋亡，通过恢复AQP3可减轻氧化损伤和凋亡，有望成为IVDD的治疗靶点。


<details>
  <summary>Details</summary>
Motivation: 研究高渗透压下AQP3在NPC细胞凋亡中的作用，以探索IVDD的潜在治疗策略。

Method: 通过体外和体内实验，评估AQP3在高渗透压下对NPC细胞的影响，并验证AQP3过表达的效果。

Result: AQP3过表达恢复PI3K/AKT/mTOR信号通路，减轻氧化损伤和凋亡，而AQP3抑制则加重ECM降解和NP组织损失。

Conclusion: AQP3缺乏通过抑制PI3K/AKT/mTOR信号通路促进NPC凋亡，是IVDD的潜在治疗靶点。

Abstract: Hyperosmolarity is a key contributor to nucleus pulposus cell (NPC) apoptosis
during intervertebral disc degeneration (IVDD). Aquaporin 3 (AQP3), a membrane
channel protein, regulates cellular osmotic balance by transporting water and
osmolytes. Although AQP3 downregulation is associated with disc degeneration,
its role in apoptosis under hyperosmotic conditions remains unclear. Here, we
demonstrate that hyperosmolarity induces AQP3 depletion, suppresses the
PI3K/AKT/mTOR signaling pathway, and promotes mitochondrial dysfunction and ROS
accumulation in NPCs. Lentiviral overexpression of AQP3 restores this pathway,
attenuates oxidative damage, and reduces apoptosis, preserving disc structure
in IVDD rat models. In contrast, pharmacological inhibition of AQP3 exacerbates
ECM catabolism and NP tissue loss. Our findings reveal that AQP3 deficiency
under hyperosmolarity contributes to NPC apoptosis via suppression of
PI3K/AKT/mTOR signaling, potentially creating a pathological cycle of disc
degeneration. These results highlight AQP3 as a promising therapeutic target
for IVDD.

</details>


### [3] [HelixDesign-Antibody: A Scalable Production-Grade Platform for Antibody Design Built on HelixFold3](https://arxiv.org/abs/2507.02345)
*Jie Gao,Jing Hu,Shanzhuo Zhang,Kunrui Zhu,Sheng Qian,Yueyang Huang,Xiaonan Zhang,Xiaomin Fang*

Main category: q-bio.BM

TL;DR: 介绍了一种基于HelixFold3的高通量抗体设计平台HelixDesign-Antibody，能够大规模生成抗体候选序列并评估其与抗原的相互作用，通过高效计算支持实现高通量筛选，验证了序列空间探索的规模化优势。


<details>
  <summary>Details</summary>
Motivation: 传统抗体发现方法耗时长、资源密集，亟需一种高效的替代方案以加速研发进程。

Method: 利用高精度结构预测模型HelixFold3构建了一个高通量平台，集成了高性能计算支持，用于生成和筛选抗体候选序列。

Result: 平台验证了其生成多样化高质量抗体的能力，并表明探索更大的序列空间可提高发现最优结合体的概率。

Conclusion: 该平台为大规模抗体设计提供了无缝、易用的解决方案，并在PaddleHelix平台上开放使用。

Abstract: Antibody engineering is essential for developing therapeutics and advancing
biomedical research. Traditional discovery methods often rely on time-consuming
and resource-intensive experimental screening. To enhance and streamline this
process, we introduce a production-grade, high-throughput platform built on
HelixFold3, HelixDesign-Antibody, which utilizes the high-accuracy structure
prediction model, HelixFold3. The platform facilitates the large-scale
generation of antibody candidate sequences and evaluates their interaction with
antigens. Integrated high-performance computing (HPC) support enables
high-throughput screening, addressing challenges such as fragmented toolchains
and high computational demands. Validation on multiple antigens showcases the
platform's ability to generate diverse and high-quality antibodies, confirming
a scaling law where exploring larger sequence spaces increases the likelihood
of identifying optimal binders. This platform provides a seamless, accessible
solution for large-scale antibody design and is available via the antibody
design page of PaddleHelix platform.

</details>


<div id='cs.AI'></div>

# cs.AI [[Back]](#toc)

### [4] [STELLA: Self-Evolving LLM Agent for Biomedical Research](https://arxiv.org/abs/2507.02004)
*Ruofan Jin,Zaixi Zhang,Mengdi Wang,Le Cong*

Main category: cs.AI

TL;DR: STELLA是一种自进化的AI代理，通过动态更新其模板库和工具库，实现自主学习和适应，显著提高了生物医学任务的准确率。


<details>
  <summary>Details</summary>
Motivation: 生物医学数据、工具和文献的快速增长导致研究领域碎片化，传统AI代理依赖静态工具集，难以适应和扩展。

Method: STELLA采用多代理架构，通过动态模板库和自动发现新工具的工具海洋机制，实现自主学习和能力提升。

Result: STELLA在多项生物医学基准测试中表现优异，准确率领先现有模型，且随着经验积累性能显著提升。

Conclusion: STELLA标志着AI代理系统的重大进展，能够动态扩展专业知识，加速生物医学发现。

Abstract: The rapid growth of biomedical data, tools, and literature has created a
fragmented research landscape that outpaces human expertise. While AI agents
offer a solution, they typically rely on static, manually curated toolsets,
limiting their ability to adapt and scale. Here, we introduce STELLA, a
self-evolving AI agent designed to overcome these limitations. STELLA employs a
multi-agent architecture that autonomously improves its own capabilities
through two core mechanisms: an evolving Template Library for reasoning
strategies and a dynamic Tool Ocean that expands as a Tool Creation Agent
automatically discovers and integrates new bioinformatics tools. This allows
STELLA to learn from experience. We demonstrate that STELLA achieves
state-of-the-art accuracy on a suite of biomedical benchmarks, scoring
approximately 26\% on Humanity's Last Exam: Biomedicine, 54\% on LAB-Bench:
DBQA, and 63\% on LAB-Bench: LitQA, outperforming leading models by up to 6
percentage points. More importantly, we show that its performance
systematically improves with experience; for instance, its accuracy on the
Humanity's Last Exam benchmark almost doubles with increased trials. STELLA
represents a significant advance towards AI Agent systems that can learn and
grow, dynamically scaling their expertise to accelerate the pace of biomedical
discovery.

</details>


### [5] [An AI-native experimental laboratory for autonomous biomolecular engineering](https://arxiv.org/abs/2507.02379)
*Mingyu Wu,Zhaoguo Wang,Jiabin Wang,Zhiyuan Dong,Jingkai Yang,Qingting Li,Tianyu Huang,Lei Zhao,Mingqiang Li,Fei Wang,Chunhai Fan,Haibo Chen*

Main category: cs.AI

TL;DR: 本文介绍了一种AI驱动的自主实验室，用于复杂科学实验，如生物分子工程，能够自主管理仪器、优化实验，并在多用户场景中提高效率。


<details>
  <summary>Details</summary>
Motivation: 实现自主科学研究的长期目标，突破传统实验的局限，支持非专家用户进行复杂实验。

Method: 采用AI原生设计，结合模型、实验和仪器的共同设计理念，实现端到端的多用户自主实验室。

Result: 该实验室能自主优化实验性能，匹配人类科学家的成果，并在多用户场景中显著提高效率和仪器利用率。

Conclusion: 这一平台为生物材料研究提供了新途径，减少对专家和资源的依赖，为大规模“科学即服务”奠定了基础。

Abstract: Autonomous scientific research, capable of independently conducting complex
experiments and serving non-specialists, represents a long-held aspiration.
Achieving it requires a fundamental paradigm shift driven by artificial
intelligence (AI). While autonomous experimental systems are emerging, they
remain confined to areas featuring singular objectives and well-defined, simple
experimental workflows, such as chemical synthesis and catalysis. We present an
AI-native autonomous laboratory, targeting highly complex scientific
experiments for applications like autonomous biomolecular engineering. This
system autonomously manages instrumentation, formulates experiment-specific
procedures and optimization heuristics, and concurrently serves multiple user
requests. Founded on a co-design philosophy of models, experiments, and
instruments, the platform supports the co-evolution of AI models and the
automation system. This establishes an end-to-end, multi-user autonomous
laboratory that handles complex, multi-objective experiments across diverse
instrumentation. Our autonomous laboratory supports fundamental nucleic acid
functions-including synthesis, transcription, amplification, and sequencing. It
also enables applications in fields such as disease diagnostics, drug
development, and information storage. Without human intervention, it
autonomously optimizes experimental performance to match state-of-the-art
results achieved by human scientists. In multi-user scenarios, the platform
significantly improves instrument utilization and experimental efficiency. This
platform paves the way for advanced biomaterials research to overcome
dependencies on experts and resource barriers, establishing a blueprint for
science-as-a-service at scale.

</details>


<div id='cs.LG'></div>

# cs.LG [[Back]](#toc)

### [6] [Guided Generation for Developable Antibodies](https://arxiv.org/abs/2507.02670)
*Siqi Zhao,Joshua Moller,Porfi Quintero-Cadena,Lood van Niekerk*

Main category: cs.LG

TL;DR: 开发一种基于扩散模型的框架，结合生**物物理******限制，优化抗体****序列****的开发性。


<details>
  <summary>Details</summary>
Motivation: 提高抗体的临床有效性需要综合考虑制造性、稳定性和安全性，这些统称为‘开发性’。传统方法难以平衡这些因素，因此需要计算工具优化抗体序列。

Method: 提出了一个引导离散扩散模型，结合从OAS提取的自然抗体序列和246种临床阶段抗体的开发性测量数据。引入了SVDD模块，在不牺牲自然性的前提下引导生成。

Result: 模型能够重现自然抗体库和获批治疗抗体的全局特征，SVDD引导下显著提高了预测开发性评分。

Conclusion: 该框架结合高通量开发性测试，可迭代设计同时满足结合性和生物物理标准的抗体。

Abstract: Therapeutic antibodies require not only high-affinity target engagement, but
also favorable manufacturability, stability, and safety profiles for clinical
effectiveness. These properties are collectively called `developability'. To
enable a computational framework for optimizing antibody sequences for
favorable developability, we introduce a guided discrete diffusion model
trained on natural paired heavy- and light-chain sequences from the Observed
Antibody Space (OAS) and quantitative developability measurements for 246
clinical-stage antibodies. To steer generation toward biophysically viable
candidates, we integrate a Soft Value-based Decoding in Diffusion (SVDD) Module
that biases sampling without compromising naturalness. In unconstrained
sampling, our model reproduces global features of both the natural repertoire
and approved therapeutics, and under SVDD guidance we achieve significant
enrichment in predicted developability scores over unguided baselines. When
combined with high-throughput developability assays, this framework enables an
iterative, ML-driven pipeline for designing antibodies that satisfy binding and
biophysical criteria in tandem.

</details>


### [7] [Hierarchical Multi-Label Contrastive Learning for Protein-Protein Interaction Prediction Across Organisms](https://arxiv.org/abs/2507.02724)
*Shiyi Liu,Buwen Liang,Yuetong Fang,Zixuan Jiang,Renjing Xu*

Main category: cs.LG

TL;DR: HIPPO是一个基于层次对比学习的蛋白质相互作用预测框架，通过多层次的生物表示匹配和对齐，实现了跨物种的零样本预测。


<details>
  <summary>Details</summary>
Motivation: 解决蛋白质相互作用预测中数据稀疏和跨物种泛化问题。

Method: 采用层次对比学习框架，结合蛋白质序列和层级属性，通过数据驱动的惩罚机制和层次对比损失函数进行训练。

Result: 在基准测试中表现优异，零样本预测能力强，适用于低数据或稀有物种的场景。

Conclusion: HIPPO为稀疏或不平衡的多物种数据提供了统一的预测框架，显著提升了预测性能。

Abstract: Recent advances in AI for science have highlighted the power of contrastive
learning in bridging heterogeneous biological data modalities. Building on this
paradigm, we propose HIPPO (HIerarchical Protein-Protein interaction prediction
across Organisms), a hierarchical contrastive framework for protein-protein
interaction(PPI) prediction, where protein sequences and their hierarchical
attributes are aligned through multi-tiered biological representation matching.
The proposed approach incorporates hierarchical contrastive loss functions that
emulate the structured relationship among functional classes of proteins. The
framework adaptively incorporates domain and family knowledge through a
data-driven penalty mechanism, enforcing consistency between the learned
embedding space and the intrinsic hierarchy of protein functions. Experiments
on benchmark datasets demonstrate that HIPPO achieves state-of-the-art
performance, outperforming existing methods and showing robustness in low-data
regimes. Notably, the model demonstrates strong zero-shot transferability to
other species without retraining, enabling reliable PPI prediction and
functional inference even in less characterized or rare organisms where
experimental data are limited. Further analysis reveals that hierarchical
feature fusion is critical for capturing conserved interaction determinants,
such as binding motifs and functional annotations. This work advances
cross-species PPI prediction and provides a unified framework for interaction
prediction in scenarios with sparse or imbalanced multi-species data.

</details>
